An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
- Conditions
- FLT3-mutated Acute Myeloid Leukemia
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03114228
- Locations
- 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT03111992
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
- Conditions
- Asthma
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT03108027
- Locations
- 🇬🇧
Novartis Investigative Site, Machester, United Kingdom
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 233
- Registration Number
- NCT03106779
- Locations
- 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Michigan Clinical Trials Office, Ann Arbor, Michigan, United States
🇺🇸Utah Huntsman Cancer Center, Salt Lake City, Utah, United States
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 460
- Registration Number
- NCT03100058
- Locations
- 🇬🇧
Novartis Investigative Site, Stevenage, United Kingdom
A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT03100500
- Locations
- 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT03100825
- Locations
- 🇯🇵
Novartis Investigative Site, Toshima ku, Tokyo, Japan
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
- Conditions
- Episodic Migraine
- Interventions
- Biological: AMG334 (70 mg) Pre-Filled Syringe (PFS)Biological: Placebo Pre-Filled Syringe (PFS)
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT03096834
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 502
- Registration Number
- NCT03096847
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT03094195
- Locations
- 🇬🇧
Novartis Investigative Site, Liverpool, United Kingdom